文献速递糖尿病

应对糖尿病异质性并推进精准医学的研究路线图

A Research Roadmap to Address the Heterogeneity of Diabetes and Advance Precision Medicine.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文介绍NIDDK糖尿病异质性倡议及未来2型糖尿病异质性研究路线图。文章回顾糖尿病分类历史,指出当前分类无法识别「非典型」糖尿病,强调遗传、生活经历、合并症和治疗影响预后风险。理解异质性有望改善诊断、预防、治疗和并发症预测。

要点

  • 当前糖尿病分类未能识别「非典型」糖尿病。
  • 糖尿病异质性贯穿个体全生命周期。
  • 理解异质性有望改善诊断、预防、治疗和并发症预测。

核心结论

  • 理解糖尿病异质性可能改善医学和公共卫生环境下的诊断、预防、治疗和并发症预测。

研究设计与样本

  • 本文介绍NIDDK糖尿病异质性倡议及未来2型糖尿病异质性研究路线图。

主要发现

  • 当前分类源于85年前基于口服葡萄糖耐量试验反应分为胰岛素敏感和胰岛素不敏感状态。
  • 约35年后提出当代1型和2型糖尿病分类。
  • 当前证据提示多种病因和病理过程导致1型和2型糖尿病,在启动、进展和临床表现上存在显著异质性。
  • 当前分类未能识别目前定义的「非典型」糖尿病。
  • 糖尿病异质性贯穿个体全生命周期,预后风险(如糖尿病并发症)受遗传、生活经历、合并症和治疗影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current classification of diabetes had its genesis over 85 years ago, when individuals with diabetes were first subclassified into insulin sensitive and insulin insensitive states based on the response to an oral glucose tolerance test. About 35 years later, the contemporary classifications of type 1 and type 2 diabetes were coined. Today's evidence, however, suggests that multiple etiologic and pathogenic processes lead to both type 1 and type 2 diabetes, reflecting significant heterogeneity in factors associated with initiation, progression, and clinical presentation of each disorder of glucose homeostasis. Further, the current classification fails to recognize what is currently defined as "atypical" diabetes. Heterogeneity of diabetes continues through the life-course of an individual, with modification of prognosis risk (eg, diabetic complications) altered by genetics, life experience, comorbidities, and therapy. Understanding the sources of heterogeneity in diabetes will likely improve diagnosis, prevention, treatment, and prediction of complications in both the medical and public health settings. Such knowledge will help inform progress in the emerging era of precision diabetes medicine. This article presents NIDDK's Heterogeneity of Diabetes Initiative and a corresponding roadmap for future research in type 2 diabetes heterogeneity.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Franks PW, Rich SS, Linder B, et al. A Research Roadmap to Address the Heterogeneity of Diabetes and Advance Precision Medicine. J Clin Endocrinol Metab. 2025. PMID: 39657245. doi:10.1210/clinem/dgae844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。